Navigation Links
DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
Date:6/3/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company presented a poster entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual Meeting, on June 1, 2013 in Chicago.

DelMar presented additional clinical data from the company's ongoing Phase I/II clinical trial with VAL-083.  The trial is a dose-escalation study designed to assess the safety and activity of VAL-083 as a potential treatment for brain cancer patients suffering from glioblastoma or secondary-progressive brain tumor who have failed standard therapies and have no viable treatment options. Three cohorts of patients have been enrolled so far, testing VAL-083 at 1.5mg/m2; 3.0mg/m2 and 5.0mg/m2.  A link to the company's poster can be found at: http://www.delmarpharma.com/DelMarASCO2013-11x17.pdf

Jeffrey Bacha , president & CEO of DelMar Pharmaceuticals, noted, "These new data presented at ASCO continue to demonstrate promise for VAL-083 as a potential treatment for cancer patients suffering from GBM as well as patients who are suffering from other cancers that have spread to the brain. Tumors of the brain are among the most challenging malignancies to treat. Median survival for patients with recurrent disease is approximately 6 months for glioblastoma multiforme.  Central nervous system metastases have evolved as a major contributor to cancer mortality because many new systemic therapies cannot reach tumors spreading to the brain."

Highlights of the DelMar ASCO
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
2. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
3. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
4. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
5. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
6. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
7. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
8. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
9. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
10. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
11. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 NxStage Medical, Inc. (NASDAQ: ... innovative dialysis products, announced today that the U.S. ... System One™ to perform hemodialysis overnight while the ... nocturnal hemodialysis. NxStage,s® System One is the first ... for this indication. Home nocturnal ...
(Date:12/22/2014)... Tenn. , Dec. 22, 2014   TRU-D ... automated, no-touch UV disinfection robot, announced today that the ... Schedule contract through November 2019.   This ... rapidly engage all levels of government purchasers, including Department ... as well as Homeland Security contacts purchasing solutions for ...
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... the treatment and management of epilepsy, today announced it will ... Conference on Wednesday, January 14, 2015, in San ... President and Chief Executive Officer, will speak at 11:00 AM ... be accessed by clicking on the Investor Relations link on ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... RELEASE AT 5 P.M. EDT MONDAY, AUG. 4/, ... and older should not be,screened for prostate cancer, and ... prostate-specific antigen (PSA) test with their clinicians,before being tested, ... Task Force. The recommendation and accompanying,evidence summary appear in ...
... percent of patients achieved SVR 12 with 48-week boceprevir-based ... combination therapy ... for 28-week boceprevir arm, KENILWORTH, N.J., Aug. 4 Schering-Plough,Corporation (NYSE: ... a Phase II study of boceprevir, its investigational,oral hepatitis C protease inhibitor. ...
Cached Medicine Technology:Task Force Says Men Age 75 and Older Should Not Be Screened For Prostate Cancer 2Task Force Says Men Age 75 and Older Should Not Be Screened For Prostate Cancer 3Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 2Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 3Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 4Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 5Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 6Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 7Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 8Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 9
(Date:12/26/2014)... 2014 Cooking and warming equipment ... of 5. This score reflects slightly positive negotiation conditions ... specialization, low switching costs and a low level of ... low availability of substitutes for cooking and warming equipment ... and aluminum, key inputs in the production process of ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... 26, 2014 Pentec Health, Inc. number ... state of Pennsylvania for 2014. The awards program, created ... of its kind in the country. The program is ... Department of Community and Economic Development, the Pennsylvania State ... the Central Penn Business Journal. , Charlie ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... da Silva on Friday issued a compulsory license ... Merck's antiretroviral Efavirenz, the AP/Forbes reports. ... a "national emergency" and issue compulsory licenses on ... Brazilian Health Minister Jose Gomes Temporao late last ...
... Johns Hopkins Childrens Center neurologists are sounding the alarm for ... In fact, nearly 3,200 children have so-called brain ... permanent neurological damage, according to Lori Jordan, M.D. ... brain tumors, says Jordan, but unlike cancer, sadly, strokes ...
... SAARC Secretariat and UNICEF, experts and policy makers are ... to plan for the future of over 10 million ... becomes public knowledge, their children are likely to face ... health centers and in schools," said Frances Turner, deputy ...
... 15-year-old Indian-American boy underwent a simultaneous liver and kidney ... the attending doctors claimed as the first such in ... a disease known as primary Hyperoxaluria, in which the ... in the kidneys, bones, heart and pancreas. Patients suffering ...
... you row merrily down the Portland streams, think again. Scientists ... the national effort to narrow down on the main pollutants ... exercise by scientists found residues of medicines and coffee sediments ... likes of Prozac, Tagamet, Benadryl, and Micatin. Caffeine was also ...
... Bill Clinton has once again lent a helping hand to ... Brazil government and drug giant Merck over pricey anti-retroviral ... Clinching a deal with two Indian pharmaceutical companies Cipla and ... provide second-line AVR drugs and a next generation one-pill-a-day drug. ...
Cached Medicine News:Health News:Childhood Strokes Linked to Whiplash, Other Traumatic Injury 2Health News:NRI Boy Underwent a Rare Dual Transplant Surgery 2Health News:Clinton Foundation Eases Over-Pricing Of AIDS Drugs Once More 2
MD Coder Charge Capture Pocket PC Edition is a charge capture tool. We have integrated the feedback from hospitals and physicians. MD Coder Charge Capture supports both the Palm OS and Pocket PC plat...
... list of disease and code numbers in ... PC PDA or Smartphone. The International Classification ... is based on the World Health Organization's ... ICD-9-CM is the official system of assigning ...
The focus of HandEchart Professional is to offer a practical and basic electronic patient record keeping system that anyone can learn in minutes....
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
Medicine Products: